Sparc binding scfvs

Patent metadata

Field	Value
Publication number	US-2016304592-A1
Application number	US-201615132647-A
Country	US
Kind code	A1
Filing date	Apr 19, 2016
Priority date	Dec 5, 2008
Publication date	Oct 20, 2016
Grant date	—

Abstract

The invention provides compositions comprising SPARC binding ScFc and its use.

First claim

1 .- 22 . (canceled)

23 . A method for treating a mammal with a disease or condition comprising:
(a) preparing a composition comprising one or more SPARC binding ScFvs whose amino acid sequences consist of SEQ ID NO: 113-116, and optionally, further comprising a pharmaceutically acceptable carrier; and (b) administering a therapeutically effective amount of the composition of step (a) to a mammal with a disease or condition.

24 . The method of claim 23 , wherein the ScFv is coupled to a therapeutic agent or a diagnostic agent.

25 . The method of claim 24 , wherein the therapeutic agent is an antibody fragment comprising a functional antibody Fc domain.

26 . The method of claim 25 , wherein the functional antibody Fc domain comprises SEQ ID NO: 118.

27 . The method of claim 23 , wherein the therapeutic agent is selected from the group consisting of a radionuclide, adriamycin, ansamycin antibiotics, asparaginase, bleomycin, busulphan, cisplatin, carboplatin, carmustine, capecitabine, chlorambucil, cytarabine, cyclophosphamide, camptothecin, dacarbazine, dactinomycin, daunorubicin, dexrazoxane, docetaxel, doxorubicin, etoposide, epothilones, floxuridine, fludarabine, fluorouracil, gemcitabine, hydroxyurea, idarubicin, ifosfamide, irinotecan, lomustine, mechlorethamine, mercaptopurine, meplhalan, methotrexate, rapamycin (sirolimus), mitomycin, mitotane, mitoxantrone, nitrosurea, paclitaxel, pamidronate, pentostatin, plicamycin, procarbazine, rituximab, streptozocin, teniposide, thioguanine, thiotepa, taxanes, vinblastine, vincristine, vinorelbine, taxol, combretastatins, discodermolides, transplatinum, 5-fluorouracil, genistein, tTF, TNF, Smarl derived p44 peptide, interferon, TRAIL, Smac, VHL, procaspase, caspase, IL-2, a non-Fc domain antibody fragment, and combinations thereof.

28 . The method of claim 24 , wherein the therapeutic or diagnostic agent is a diagnostic agent selected from the group consisting of radioactive agents, MRI contrast agents, X-ray contrast agents, ultrasound contrast agents, and PET contrast agents.

29 . The method of claim 24 , wherein the disease or condition is a cancer.

30 . The method of claim 24 , wherein the mammal is a human.

Assignees

• Abraxis Bioscience Llc

Inventors

• Trieu Vuong

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• A61P9/10

  for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title